PolarityTE, Inc. (PTE)
| Market Cap | 97.53M |
| Revenue (ttm) | 8.00M |
| Net Income (ttm) | -53.94M |
| Shares Out | 38.76M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $1.43 |
| Previous Close | $1.46 |
| Change ($) | -0.03 |
| Change (%) | -2.05% |
| Day's Open | 1.51 |
| Day's Range | 1.39 - 1.57 |
| Day's Volume | 2,295,778 |
| 52-Week Range | 0.55 - 2.38 |
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H...
SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide thi...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/1...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrol...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors h...
PolarityTE (PTE) stock is soaring higher on Friday as investors prepare for its participation in an upcoming event on Monday. The post PTE Stock Alert: 7 Things for Investors to Know About Pol...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H...
PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. ...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissu...
PolarityTE, Inc. (PTE) CEO David Seaburg On Q3 2020 Results - Earnings Call Transcript
PolarityTE, Inc.'s (PTE) CEO David Seaburg on Q3 2020 Results - Earnings Call Transcript
Shares of PolarityTE (NASDAQ:PTE) moved higher by 7.3% in pre-market trading after the company reported Q3 results.
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the thir...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submi...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 a...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the Nation...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlle...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M.
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C.
PolarityTE, Inc. (PTE) CEO David Seaburg on Q2 2020 Results - Earnings Call Transcript
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the seco...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors.
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 ...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center random...
SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized co...
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
It is possible that the markets have run too far making today ideal for taking a few short positions. According to our deep learning algorithms, these are the ones to go after.
PolarityTE's (PTE) CEO David Seaburg on Q1 2020 Results - Earnings Call Transcript
Shares of PolarityTE (NASDAQ:PTE) were flat in pre-market trading after the company reported Q1 results.
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
PolarityTE, Inc.'s (PTE) Management on Q4 2019 Results - Earnings Call Transcript
Shares of PolarityTE Inc. plummeted 46% in premarket trading Wednesday, putting them on track to open at a record low, after the regenerative tissue products and biomaterials company said it p...
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.
PolarityTE, Inc. (PTE) Management on Q3 2019 Results - Earnings Call Transcript
It was a busy few months for PolarityTE including a leadership change and short-term focus shift. Both are welcome, but there is a huge tail risk involved.
PolarityTE, Inc. (PTE) Management on Q2 2019 Results - Earnings Call Transcript
SkinTE is a transformational alternative to STSGs (split-thickness skin grafts), the standard-of-care for severe burns and wounds.
PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
According to GuruFocus Insider Data, the recent CFO buys were: Freeport-McMoRan Inc, PolarityTE Inc. & Coeur Mining Inc.
Polarityte Inc (NASDAQ: PTE) shares were seeing an upward bounce Monday in reaction to a clinical trial readout at the American Diabetes Association's 79th Scientific Sessions conference.
PolarityTE has developed a regenerative medical technology that is already showing outstanding results in the clinic.
About PTE
PolarityTE, a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the ini... [Read more...]
| Industry Biotechnology | IPO Date Aug 13, 1999 |
| CEO Denver Lough | Employees 153 |
| Stock Exchange NASDAQ | Ticker Symbol PTE |
Financial Performance
In 2019, PolarityTE's revenue was $5.65 million, an increase of 261.61% compared to the previous year's $1.56 million. Losses were -$92.49 million, 41.3% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for PolarityTE stock is "Buy." The 12-month stock price forecast is 3.00, which is an increase of 109.79% from the latest price.